Currently Viewing:
Cost-Sharing Roundtable — The Patient Assistance Safety Net: How Many Need Help? How Many Are Helped?
Addressing Financial Concerns at the Outset to Improve Patient Outcomes
March 02, 2018
Financial Burden an Unintended Outcome of Cancer Care
March 02, 2018
Michele McCourt Discusses Growing Financial Hardships for Patients With Cancer
March 03, 2018
M. Kristina Wharton on the Role of Federally Qualified Health Centers
March 04, 2018
Where Does the Existing Healthcare Safety Net Fall Short?
March 05, 2018
Cost-Sharing Roundtable—Introduction
March 05, 2018
Patient Education Vital for Improved Medicare Access, Say Panelists
March 06, 2018
Policy Improvement Areas to Reduce Financial Hardship
March 07, 2018
Dr Todd Yezefski Discusses Using Financial Navigator Programs
March 08, 2018
Ed Haislmaier on Policy Changes That Impact Healthcare Financial Burdens
March 09, 2018
Leigh Purvis Discusses the Burden of High Prescription Drug Costs
March 14, 2018
Ed Haislmaier: Impact of Business Coalitions on Healthcare Costs
March 23, 2018
Dan Klein on Lack of Cost Sharing in Medicare, Drugs Coming Down the Pipeline
March 27, 2018
Michele McCourt Discusses Impact of High Costs for Patients With Cancer
March 27, 2018
Kristina Wharton Analyzes the Health of the Population Using FQHCs
March 29, 2018
Dr Todd Yezefski Discusses the Financial Hardships of Cancer Treatment
March 30, 2018
Leigh Purvis on Out-of-Pocket Costs for Medicare Beneficiaries
March 31, 2018
Ed Haislmaier: Medicare Is "Stuck in a Time Warp"
April 04, 2018
Dan Klein Outlines Policy Changes to Strengthen the Safety Net
April 05, 2018
Kristina Wharton Discusses Services Provided at Federally Qualified Health Centers
April 09, 2018
Dr Todd Yezefski on the Benefits of Financial Navigators in Oncology
April 14, 2018
Ed Haislmaier on Efforts to Lower Drug Costs
April 15, 2018
Currently Reading
Michele McCourt on Potential New Therapies for Patients With Cancer
April 17, 2018
Dan Klein Explains the Need for Patient Assistance Foundations
April 22, 2018

Michele McCourt on Potential New Therapies for Patients With Cancer

The high cost of new, innovative cancer treatments coming to market makes these therapies inaccessible to a lot of patients, said Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation.


The high cost of new, innovative cancer treatments coming to market makes these therapies inaccessible to a lot of patients, said Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation.

Transcript

What impact will new, potentially curative therapies have financially on patients and the healthcare system?

New, innovative treatments that are coming on the market are wonderful. But, if patients can’t access them then they are ineffective. These new treatments that are coming, I don’t really see what we’re seeing with how much they are costing but I don’t see them as accessible to a lot of these patients unless you have really good coverage. It depends on the benefit design and it depends on the medication. So, if it does fall under their medical, and if they are able to get it through their hospital coverage it may be affordable.

I don’t really know enough about the CAR Ts, but from the few that have come to market they are with a pretty heavy price tag. Although, if they are successful, they have the potential of really saving lives. I think the jury is still out on how that will affect patients and how accessible.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!